Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Attralus buys in brain shuttle tech to cross BBB
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2401)
•••
Comment by JDavenporton Nov 23, 2022 2:05pm
154 Views
Post# 35122756

RE:RE:Attralus buys in brain shuttle tech to cross BBB

RE:RE:Attralus buys in brain shuttle tech to cross BBBI misspoke a little about other technologies not using the LRP-1 receptor. Angiochem's Angiopep-2 uses that receptor but, if I recall correctly, Angiopep-2 has difficulty decoupling from the LRP-1 receptor in the endosome, preventing the LRP-1 receptor from recycling back to the BBB endothelial cell surface.

xB3-drugs, on the other hand, decouple easily from the LRP-1 receptor, allowing the receptor to recycle back to the BBB cell surface in about 30 minutes. This rapid recycling is one of the reasons that xB3 can transport more drug than other technologies. Any given LRP-1 receptor can continue to transport an xB3-drug across the BBB every 30 minutes as long as the drug remains in the bloodstream. (This is all from memory and I will humbly submit to any corrections.)

I don't think anybody considers AngioPep-2 to be a threat to any of the receptor-mediated transcytosis technologies.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities